Insider · CIK 0001236447

SCHIMMEL PAUL

Reports to the SEC for 6 companies · SAN DIEGO, CA

sec.gov

Transactions

Companies

Filings

CIK

0001236447

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-05-27	ATYRaTYR PHARMA INCP Purchase	Director	PPurchase	+100K sh	$0.50	+$49.6K	779,143
2026-05-11	ATYRaTYR PHARMA INC · Stock Option (right to buy)A Award	Director	AAward	+50K sh	—	—	50,000
2025-10-09	ATYRaTYR PHARMA INCP Purchase	Director	PPurchase	+318K sh	$0.94	+$299K	1,413,023
2025-10-08	ATYRaTYR PHARMA INCP Purchase	Director	PPurchase	+682K sh	$0.90	+$612K	1,095,024
2025-05-01	ATYRaTYR PHARMA INC · Stock Option (right to buy)A Award	Director	AAward	+50K sh	—	—	50,000
2024-07-24	ATYRaTYR PHARMA INCP Purchase	Director	PPurchase	+52.3K sh	$1.93	+$101K	413,023
2024-07-23	ATYRaTYR PHARMA INCP Purchase	Director	PPurchase	+6,648 sh	$1.82	+$12.1K	360,723
2024-07-22	ATYRaTYR PHARMA INCP Purchase	Director	PPurchase	+41.1K sh	$1.74	+$71.5K	354,075
2024-05-22	ATYRaTYR PHARMA INC · Stock Option (right to buy)A Award	Director	AAward	+24K sh	—	—	24,000
2023-05-17	ATYRaTYR PHARMA INC · Stock Option (right to buy)A Award	Director	AAward	+12K sh	—	—	12,000
2023-05-10	ATYRaTYR PHARMA INCP Purchase	Director	PPurchase	+200K sh	$2.25	+$450K	313,023
2023-04-26	ATYRaTYR PHARMA INCM Exercise/Conversion	Director	MExercise/Conversion	+6,000 sh	—	—	8,890
2023-04-26	ATYRaTYR PHARMA INC · Restricted Stock UnitM Exercise/Conversion	Director	MExercise/Conversion	−6,000 sh	—	—	0
2022-04-26	ATYRaTYR PHARMA INC · Restricted Stock UnitsA Award	Director	AAward	+6,000 sh	—	—	6,000
2021-09-20	ATYRaTYR PHARMA INCP Purchase	Director	PPurchase	+250K sh	$8.00	+$2M	252,890
2021-09-20	ATYRaTYR PHARMA INCG Gift	Director	GGift	−250K sh	—	—	2,890
2021-09-20	ATYRaTYR PHARMA INCG Gift	Director	GGift	+250K sh	—	—	679,143
2021-05-18	ATYRaTYR PHARMA INCP Purchase	Director	PPurchase	+50K sh	$3.98	+$199K	113,023
2021-04-28	ATYRaTYR PHARMA INC · Stock Option (right to buy)A Award	Director	AAward	+1,428 sh	—	—	1,428
2020-05-20	ATYRaTYR PHARMA INCS Sale	Director	SSale	−8,447 sh	$3.64	−$30.7K	429,143
2020-05-06	ATYRaTYR PHARMA INC · Stock Option (right to buy)A Award	Director	AAward	+1,428 sh	—	—	1,428
2020-02-10	ATYRaTYR PHARMA INCP Purchase	Director	PPurchase	+254K sh	$4.25	+$1.08M	437,590
2019-10-04	FBRXForte Biosciences, Inc. · Stock Option (right to buy)A Award	Director	AAward	+7,500 sh	—	—	7,500
2019-07-01	ALNYALNYLAM PHARMACEUTICALS, INC. · Stock Option (right to buy)A Award	Director	AAward	+9,000 sh	—	—	9,000
2019-05-29	FBRXForte Biosciences, Inc. · Stock option (right to buy)A Award	Director	AAward	+20K sh	—	—	20,000
2019-05-08	ATYRaTYR PHARMA INC · Stock Option (right to buy)A Award	Director	AAward	+20K sh	—	—	20,000
2019-04-12	ATYRaTYR PHARMA INCA Award	Director	AAward	+1.85M sh	$0.54	+$1M	2,570,242
2018-11-26	ATYRaTYR PHARMA INCP Purchase	Director	PPurchase	+147K sh	$0.54	+$79.8K	882,302
2018-09-04	ATYRaTYR PHARMA INCP Purchase	Director	PPurchase	+20.7K sh	$0.76	+$15.7K	735,077
2018-08-31	ATYRaTYR PHARMA INCP Purchase	Director	PPurchase	+22K sh	$0.72	+$15.8K	714,328
2018-08-30	ATYRaTYR PHARMA INCP Purchase	Director	PPurchase	+89.3K sh	$0.76	+$67.5K	692,328
2018-08-29	ATYRaTYR PHARMA INCP Purchase	Director	PPurchase	+75.1K sh	$0.72	+$54.1K	603,053
2018-06-21	FBRXForte Biosciences, Inc. · Stock option (right to buy)A Award	Director	AAward	+20K sh	—	—	20,000
2018-06-20	ALNYALNYLAM PHARMACEUTICALS, INC. · Stock Option (right to buy)A Award	Director	AAward	+9,000 sh	—	—	9,000
2018-05-18	ATYRaTYR PHARMA INCP Purchase	Director	PPurchase	+150K sh	$1.00	+$149K	527,917
2018-05-15	ATYRaTYR PHARMA INC · Stock Option (right to buy)A Award	Director	AAward	+20K sh	—	—	20,000
2018-03-13	ALNYALNYLAM PHARMACEUTICALS, INC.M Exercise/Conversion	Director	MExercise/Conversion	+10K sh	$30.09	+$301K	10,000
2018-03-13	ALNYALNYLAM PHARMACEUTICALS, INC.M Exercise/Conversion	Director	MExercise/Conversion	+2,823 sh	$63.86	+$180K	12,823
2018-03-13	ALNYALNYLAM PHARMACEUTICALS, INC.M Exercise/Conversion	Director	MExercise/Conversion	+15K sh	$59.25	+$889K	27,823
2018-03-13	ALNYALNYLAM PHARMACEUTICALS, INC.S Sale	Director	SSale	−27.8K sh	$150.00	−$4.17M	0
2018-03-13	ALNYALNYLAM PHARMACEUTICALS, INC. · Stock Option (right to buy)M Exercise/Conversion	Director	MExercise/Conversion	−15K sh	—	—	0
2018-03-13	ALNYALNYLAM PHARMACEUTICALS, INC. · Stock Option (right to buy)M Exercise/Conversion	Director	MExercise/Conversion	−2,823 sh	—	—	0
2018-03-13	ALNYALNYLAM PHARMACEUTICALS, INC. · Stock Option (right to buy)M Exercise/Conversion	Director	MExercise/Conversion	−10K sh	—	—	0
2017-08-31	ATYRaTYR PHARMA INCP Purchase	Director	PPurchase	+94.3K sh	$2.65	+$250K	377,917
2017-08-31	ATYRaTYR PHARMA INC · Warrant to Purchase Common StockP Purchase	Director	PPurchase	+35.4K sh	—	—	35,376
2017-06-02	ALNYALNYLAM PHARMACEUTICALS, INC. · Stock Option (right to buy)A Award	Director	AAward	+11.3K sh	—	—	11,250
2017-05-09	ATYRaTYR PHARMA INC · Stock Option (right to buy)A Award	Director	AAward	+20K sh	—	—	20,000
2017-04-19	FBRXForte Biosciences, Inc.C Conversion	Director	CConversion	+23.5K sh	—	—	23,464
2017-04-19	FBRXForte Biosciences, Inc.C Conversion	Director	CConversion	+4,117 sh	—	—	4,117
2017-04-19	FBRXForte Biosciences, Inc.C Conversion	Director	CConversion	+3,623 sh	—	—	3,623

Recent filings

Accepted (ET)
May 284
SCHIMMEL PAUL0001236447-26-000006
SEC(opens sec.gov)
May 134
SCHIMMEL PAUL0001236447-26-000003
SEC(opens sec.gov)
Oct 94
SCHIMMEL PAUL0001193125-25-236131
SEC(opens sec.gov)
May 24
SCHIMMEL PAUL0000950170-25-062945
SEC(opens sec.gov)
Jul 244
SCHIMMEL PAUL0000950170-24-086159
SEC(opens sec.gov)
May 234
SCHIMMEL PAUL0000950170-24-064218
SEC(opens sec.gov)
May 194
SCHIMMEL PAUL0001209191-23-031020
SEC(opens sec.gov)
May 114
SCHIMMEL PAUL0001209191-23-028607
SEC(opens sec.gov)
Apr 284
SCHIMMEL PAUL0001209191-23-026067
SEC(opens sec.gov)
Apr 284
SCHIMMEL PAUL0001209191-22-026094
SEC(opens sec.gov)
Sep 224
SCHIMMEL PAUL0001209191-21-057339
SEC(opens sec.gov)
May 204
SCHIMMEL PAUL0001209191-21-034293
SEC(opens sec.gov)
Apr 294
SCHIMMEL PAUL0001209191-21-029126
SEC(opens sec.gov)
May 224
SCHIMMEL PAUL0001209191-20-031886
SEC(opens sec.gov)

Companies

Address

C/O ATYR PHARMA, INC. 10240 SORRENTO VALLEY ROAD, SUITE 300

SAN DIEGO, CA, 92121